GLP-2 15mg

What is GLP-2?

GLP-2 (LY3298176) is a synthetic peptide engineered for laboratory research, functioning as a dual-agonist targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This 39-amino-acid peptide is modified with a C20 fatty diacid moiety via acylation technology, extending its research-ready half-life to approximately five days.

This prolonged stability, combined with its ability to engage both GLP-1 and GIP receptors, positions GLP-2 as a powerful tool for preclinical studies investigating metabolic disorders and tissue repair processes. Unlike selective GLP-1 receptor agonists, GLP-2’s dual agonism, often termed a “twincretin,” offers synergistic effects on glucose homeostasis, lipid metabolism, and appetite regulation.

Each 15mg vial from Protide Health is supplied as a high-purity, lyophilized powder for controlled laboratory reconstitution. To ensure precise protocol design, investigators can utilize the peptide dosage calculator.

• Peptide Architecture: Synthetic 39-amino-acid peptide based on a modified GIP sequence.

• Vial Content: 15mg lyophilized powder for research reconstitution.

• Pharmacokinetics: C20 fatty diacid conjugation supports once-weekly dosing in models.

• Primary Focus: Metabolic health, glucose handling, and adipose tissue function.

Chemical and Structural Properties of GLP-2 Peptide

GLP-2 is a synthetic analog of the native GIP sequence, modified to activate both GIP and GLP-1 receptors with high potency. Its structure includes a C20 fatty diacid linked via a spacer, enabling strong albumin binding in plasma, which prolongs its half-life and supports consistent exposure in animal models.

The peptide is lyophilized for stability, requiring storage at -20°C or below to maintain bioactivity during extended experimental protocols. Preclinical studies have shown that GLP-2’s affinity for GIP receptors is comparable to native GIP, while its affinity for GLP-1 receptors is approximately five times weaker than native GLP-1, creating a unique imbalanced dual-agonist profile. PubMed

• Format: Lyophilized for stability at -20°C or lower.

• Molecular Modification: C20 fatty diacid conjugation extends half-life to ~5 days.

• Receptor Affinity: Imbalanced dual agonism with comparable GIP and reduced GLP-1 receptor affinity.

Mechanisms of Action

GLP-2’s dual agonism of GLP-1 and GIP receptors underpins its efficacy in preclinical research, enabling modulation of metabolic and regenerative pathways. The peptide’s ability to engage both incretin hormone receptors produces synergistic effects on insulin secretion and lipid metabolism.

• GLP-1 Receptor Agonism: Stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, and reduces food intake in models. Molecular Metabolism

• GIP Receptor Agonism: Enhances insulin secretion and improves lipid clearance in adipose tissue. Preclinical studies demonstrated reduced triglyceride levels and increased lipoprotein lipase activity. Cell Metabolism

• Adipocyte Nutrient Metabolism: Modulates post-prandial lipid clearance into adipose tissue, reducing ectopic lipid deposition.

• Anti-Inflammatory Effects: Reduces inflammatory markers, supporting tissue repair. A 2025 study showed decreased hepatic inflammation in MAFLD mouse models. Lipids in Health and Disease

GLP-2 Peptide Research

1. GLP-2 and Metabolic Health Models

GLP-2 reduced body weight by up to 20% in diet-induced obese (DIO) mice, driven by fat mass loss and increased energy expenditure. These models help researchers understand the neuroendocrine signaling involved in long-term weight management. NEJM

2. Type 2 Diabetes Studies

Improved glycemic control and insulin sensitivity have been observed in diabetic rodents, with significant HbA1c reductions reported in clinical trial summaries. This makes GLP-2 a primary tool for studying insulin handling in experimental systems. The Lancet

3. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

GLP-2 research focuses on reducing hepatic triglycerides and inflammation. Studies in high-fat diet (HFD) mice suggest potential hepatoprotective effects and biomarkers of improved liver health. Nature Medicine

4. Cardiovascular and Adipose Tissue Research

Researchers examine improved lipid profiles and reduced vascular inflammation in obese rats. Additionally, studies into adipose tissue function show enhanced lipid clearance and storage, reducing ectopic fat accumulation. Cell Metabolism

Research Considerations and Limitations

Preclinical research with GLP-2 requires careful consideration of regulatory and scientific factors to ensure valid results.

• Regulatory Compliance: Restricted to laboratory research; not approved for human consumption.

• Dosing Protocols: Subcutaneous doses require calibration for model-specific pharmacokinetics.

• Stability Handling: Susceptibility to enzymatic degradation requires strict storage at -20°C and standardized reconstitution protocols.

GLP-2 Peptide Specifications Table

GLP-2 Peptide FAQs

What is GLP-2 peptide used for in research?

In research, GLP-2 peptide is used to study the combined effects of GIP and GLP-1 receptor activation. This “twincretin” approach allows scientists to investigate insulin response, appetite suppression, and hepatic lipid management in metabolic models. Molecular Metabolism

How is GLP-2 peptide 15mg typically stored in a lab?

Labs store GLP-2 peptide 15mg vials as lyophilized powder at -20°C or lower to ensure long-term stability. Once reconstituted, aliquoting is recommended to avoid repeated freeze-thaw cycles that can degrade the peptide chain.

What is the advantage of a dual agonist in research?

Dual agonists like GLP-2 allow researchers to explore synergistic pathways. While GLP-1 receptor activation is known for glucose control, the addition of GIP receptor agonism is studied for its potential to improve lipid clearance and energy expenditure.

Conclusion: Summary of GLP-2 Peptide for Research

GLP-2 is a transformative dual-agonist peptide for preclinical research in metabolic regulation and tissue repair. Its synergistic effects on insulin secretion, lipid metabolism, and inflammation enable comprehensive studies in obesity, type 2 diabetes, and liver fat models. With its five-day half-life and lyophilized stability, GLP-2 is an ideal tool for long-term experimental protocols in controlled laboratory environments.

Citations

• Coskun T et al., 2018. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Molecular Metabolism.

• Jastreboff AM et al., 2023. GLP-2 for obesity. New England Journal of Medicine.

• Sanyal AJ et al., 2024. GLP-2 for metabolic dysfunction-associated steatotic liver disease. Nature Medicine.

• Ma J et al., 2024. Effects of GLP-2 on diabetic kidney disease. Endocrine.

• Regmi A et al., 2024. GLP-2 modulates adipocyte nutrient metabolism. Cell Metabolism.

Legal Disclaimer for GLP-2 Peptide

The information provided in this description is for research purposes only. The GLP-2 peptide is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Researchers must comply with all applicable local, state, and federal regulations. Products sold by Protide Health are for laboratory research purposes only and are not intended for human consumption, medical use, or veterinary use.